Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP
Founder-led company
Acurx Pharmaceuticals stock price today
$5.05
+4.15
+464.88%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 14 hours
Acurx Pharmaceuticals stock price monthly change
-61.30%
month
Acurx Pharmaceuticals stock price quarterly change
-61.30%
quarter
Acurx Pharmaceuticals stock price yearly change
-77.82%
year
Acurx Pharmaceuticals key metrics
Market Cap | 13.64M |
Enterprise value | N/A |
P/E | -3.03 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 3.92 |
PEG ratio | -0.64 |
EPS | -1.18 |
Revenue | N/A |
EBITDA | -16.05M |
Income | -16.05M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAcurx Pharmaceuticals stock price history
Acurx Pharmaceuticals stock forecast
Acurx Pharmaceuticals financial statements
| Jun 2023 | 0 | -3.44M | |
|---|---|---|---|
| Sep 2023 | 0 | -3.11M | |
| Dec 2023 | 0 | -5.11M | |
| Mar 2024 | 0 | -4.37M |
| 2025 | 10.34M | -25.77M | -249.18% |
|---|---|---|---|
| 2026 | 16.03M | -16.74M | -104.41% |
| 2027 | 3.53M | -21.54M | -609.38% |
| 2028 | 50.61M | -12.79M | -25.29% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-13 | -0.28 | -0.24 |
|---|---|---|
| 2024-03-15 | -0.26 | -0.38 |
| Jun 2023 | 9235777 | 3.01M | 32.69% |
|---|---|---|---|
| Sep 2023 | 7158051 | 3.22M | 45.03% |
| Dec 2023 | 7709123 | 3.04M | 39.47% |
| Mar 2024 | 9108834 | 3.11M | 34.15% |
| Jun 2023 | -1.57M | 0 | 3.54M |
|---|---|---|---|
| Sep 2023 | -2.09M | 0 | 0 |
| Dec 2023 | -4.19M | 0 | 4.61M |
| Mar 2024 | -3.06M | 0 | 4.50M |
Acurx Pharmaceuticals alternative data
| Aug 2023 | 4 |
|---|---|
| Sep 2023 | 4 |
| Oct 2023 | 4 |
| Nov 2023 | 4 |
| Dec 2023 | 4 |
| Jan 2024 | 4 |
| Feb 2024 | 4 |
| Mar 2024 | 4 |
| Apr 2024 | 4 |
| May 2024 | 4 |
| Jun 2024 | 4 |
| Jul 2024 | 4 |
Acurx Pharmaceuticals other data
0.44%
-11.26%
of ACXP is owned by hedge funds
48.04K
-1.25M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2021 | 15395 | 0 |
| Jul 2022 | 118422 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | SAILER CARL director | Common Stock | 19,737 | $3.55 | $70,066 | ||
Option | SAILER CARL director | Warrants for Common Stock | 19,737 | $3.55 | $70,066 | ||
Option | DELUCCIA ROBERT J director, 10 perc.. | Common Stock | 19,737 | $3.55 | $70,066 | ||
Option | DELUCCIA ROBERT J director, 10 perc.. | Warrants for Common Stock | 19,737 | $3.55 | $70,066 | ||
Option | LUCI DAVID P director, 10 percent owner, off.. | Common Stock | 19,737 | $3.55 | $70,066 | ||
Option | LUCI DAVID P director, 10 percent owner, off.. | Warrants for Common Stock | 19,737 | $3.55 | $70,066 | ||
Purchase | LUCI DAVID P director, 10 percent owner, off.. | Warrants for Common Stock | 19,737 | $3.55 | $70,066 | ||
Purchase | DELUCCIA ROBERT J director, 10 perc.. | Warrants for Common Stock | 19,737 | $3.55 | $70,066 | ||
Purchase | DELUCCIA ROBERT J director, 10 perc.. | Common Stock | 19,737 | $3.8 | $75,001 | ||
Purchase | SAILER CARL director | Warrants for Common Stock | 19,737 | $3.55 | $70,066 |
| Patent |
|---|
Application Filling date: 2 Apr 2021 Issue date: 14 Apr 2022 |
Application Filling date: 20 Jul 2021 Issue date: 27 Jan 2022 |
Grant Filling date: 15 Jun 2020 Issue date: 11 May 2021 |
Grant Filling date: 15 Jun 2020 Issue date: 17 Nov 2020 |
Application Filling date: 15 Jun 2020 Issue date: 1 Oct 2020 |
Application Filling date: 15 Jun 2020 Issue date: 1 Oct 2020 |
Grant Filling date: 19 Dec 2019 Issue date: 28 Jul 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 15 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 18 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 14 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Robert J. DeLuccia (1946) Co-Founder & Executive Chairman | $342,750 |
Mr. David P. Luci CPA, CPA, J.D., Esq. (1967) Co-Founder, Pres, Chief Executive Officer & Director | $321,210 |
Mr. Robert G. Shawah CPA (1967) Co-Founder & Chief Financial Officer | $90,000 |
-
What's the price of Acurx Pharmaceuticals stock today?
One share of Acurx Pharmaceuticals stock can currently be purchased for approximately $5.05.
-
When is Acurx Pharmaceuticals's next earnings date?
Unfortunately, Acurx Pharmaceuticals's (ACXP) next earnings date is currently unknown.
-
Does Acurx Pharmaceuticals pay dividends?
No, Acurx Pharmaceuticals does not pay dividends.
-
How much money does Acurx Pharmaceuticals make?
Acurx Pharmaceuticals has a market capitalization of 13.64M. Acurx Pharmaceuticals made a loss 14.58M US dollars in net income (profit) last year or -$0.38 on an earnings per share basis.
-
What is Acurx Pharmaceuticals's stock symbol?
Acurx Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ACXP".
-
What is Acurx Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Acurx Pharmaceuticals?
Shares of Acurx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Acurx Pharmaceuticals's key executives?
Acurx Pharmaceuticals's management team includes the following people:
- Mr. Robert J. DeLuccia Co-Founder & Executive Chairman(age: 79, pay: $342,750)
- Mr. David P. Luci CPA, CPA, J.D., Esq. Co-Founder, Pres, Chief Executive Officer & Director(age: 58, pay: $321,210)
- Mr. Robert G. Shawah CPA Co-Founder & Chief Financial Officer(age: 58, pay: $90,000)
-
Is Acurx Pharmaceuticals founder-led company?
Yes, Acurx Pharmaceuticals is a company led by its founders Mr. Robert J. DeLuccia, Mr. David P. Luci CPA, CPA, J.D., Esq. and Mr. Robert G. Shawah CPA.
-
How many employees does Acurx Pharmaceuticals have?
As Jul 2024, Acurx Pharmaceuticals employs 4 workers.
-
When Acurx Pharmaceuticals went public?
Acurx Pharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 25 Jun 2021.
-
What is Acurx Pharmaceuticals's official website?
The official website for Acurx Pharmaceuticals is acurxpharma.com.
-
Where are Acurx Pharmaceuticals's headquarters?
Acurx Pharmaceuticals is headquartered at 259 Liberty Avenue, Staten Island, NY.
-
How can i contact Acurx Pharmaceuticals?
Acurx Pharmaceuticals's mailing address is 259 Liberty Avenue, Staten Island, NY and company can be reached via phone at +91 75331469.
Acurx Pharmaceuticals company profile:
Acurx Pharmaceuticals, Inc.
acurxpharma.comExchange:
NASDAQ
Full time employees:
4
Industry:
Biotechnology
Sector:
Healthcare
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
259 Liberty Avenue
Staten Island, NY 10305
Staten Island, NY 10305
CIK: 0001736243
ISIN: US00510M1045
CUSIP: 00510M104
